Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ammonium chloride + pomaglumetad methionil
- Development stage
- Unknown
- Lead developer
- Eli Lilly
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Ammonium chloride + LY2140023 is an investigational drug combination evaluated in a Phase 1 clinical trial (NCT01440478) to study the impact of urinary pH variations on the pharmacokinetics of the antipsychotic prodrug LY2140023 (pomaglumetad methionil) and its active metabolite LY404039. LY2140023 is an oral prodrug of LY404039, which acts as a selective agonist of metabotropic glutamate 2/3 (mGlu2/3) receptors. Originally developed by Eli Lilly and Company and later licensed to Denovo Biopharma, LY2140023 has been investigated for the treatment of schizophrenia. In this specific pharmacokinetic study, ammonium chloride was administered as a urinary acidifier to lower urinary pH, allowing researchers to determine how changes in urine acidity affect the renal clearance and overall disposition of LY2140023 and its active metabolite.
- Other names
- ammonium chloride + LY2140023ammonium chloride + pomaglumetad methionilammonium chloride + pomaglumetad methionil hydrate
02
Targets
GRM2 (mGluR2)GRM3 (mGluR3)SLC15 (SLC15 family)
Beyond the preview
Go deeper on ammonium chloride + pomaglumetad methionil.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ammonium chloride + pomaglumetad methionil.